CHEMVET PHARMA ApS: Financial statements 2016
CVR: 20386908
Source: annual report 2016, Danish Business Authority
01/01/2016 – 31/12/2016
CHEMVET PHARMA ApS (CVR 20386908) has filed annual accounts for 2016. In 2016, the company reported a gross profit of DKK 868,186 and a net result of DKK 61,242 compared with DKK 579,485 the year before. That is a decrease of 48.5% compared with the year before. Equity in the 2016 report amounted to DKK 2,875,790. The solvency ratio was 68.4%. The company had 2 employees in the financial year.
- Gross Profit
- DKK 868,186
- Profit/Loss
- DKK 61,242
- Equity
- DKK 2,875,790
- Total Assets
- DKK 4,203,145
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2016 | - | 868 t. | 61 t. | 2.9 mio. | 2 |
| 2015 | - | 1.7 mio. | 579 t. | 2.5 mio. | 2 |
| 2014 | - | 1.9 mio. | 699 t. | 1.9 mio. | - |
| 2013 | - | 606 t. | -67 t. | 1.2 mio. | - |
Official annual report
Find more companies like CHEMVET PHARMA ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2016
CHEMVET PHARMA ApS has published its interim report for the period July 1, 2015 – December 31, 2015.
As of February 8, 2016, Frank Arvé Christensen has joined the board of directors of CHEMVET PHARMA ApS.
As of February 7, 2016, Frank Arvé Christensen has left the board of directors of CHEMVET PHARMA ApS.
About CHEMVET PHARMA ApS
CHEMVET PHARMA ApS is a Danish company of the type Anpartsselskab based in Silkeborg, founded in 1997. The company is registered under the industry Engroshandel med andre fødevarer. The company was previously named ApS KBIL 9 NR. 2027. The management consists of Frank Arvé Christensen. The board consists of Sarah Arvé (chair), Frank Arvé Christensen and Maria Arvé Brostrøm. The company is owned by Frank Arvé Christensen, Sarah Arvé and Maria Arvé Brostrøm. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 1,700,759 and a net result of DKK 970,939 compared with DKK 807,613 the year before. Equity in the 2025 report amounted to DKK 3,822,846.